The Rise of India’s Drug Industry and The Rise of Bangladesh’s Textile Trade At first, India’s trade industry was one that was known for being an international outcast in the pharmaceutical industry. The counterfeit drugs that they were producing and selling eventually was revealed by the Western and Japanese pharmaceutical companies. Therefore, they were not allowed to sell their products in any developed markets considering that they dishonored intellectual property rights. Intellectual property rights include any patents, copyrights, or trademarks associated with a typical good or invention. The copies of untested products that India caused any other foreign drug company caused any other foreign company to turn the other way. Those companies refused to participate in or partner with any of the Indian’s productions, which really limited business prospects of Indian companies. Furthermore, the only products that India was able to sell in the United States were inexpensive, generic drugs that had expired patents. This caused India to have a lot less profits and business opportunities. International trade is meant to offer consumers and other countries a chance to be exposed to new products worldwide, but considering India’s knockoff pharmaceuticals were unable to be sold they needed to make a change. In 2005, India signed an arrangement with the World Trade Organization, bringing the country into an agreement with any rules on intellectual property. India was
Critics have pointed a finger at the unethical use of intellectual property in the pharmaceutical industry claiming it is being used to set prices far above what those in third world countries can afford. Given that a good number of the raw material came from these regions, it is unethical to use intellectual property
The case consists of two major pharmaceutical companies that joint to collaborate their research and pharmaceutical technologies to start a joint venture in India. Both have valuable resources that have benefited both companies during the joint venture. Now both are questioning if there is still any value in maintaining the joint venture in India and will be deciding what will be the best route to take. Ranbaxy Laboratories wants to be bought out, but Eli Lilly is worried of the financial implications of such move.
Economic: Globalization of the pharmaceutical industry is an exciting opportunity to have research and development done at cheaper prices in other countries. However, this could be a double edged sword for companies because it is easy for other countries, such as India, to produce generic versions of the drug in bulk.
"In the past two decades or so, health care has been commercialized as never before, and professionalism in medicine seems to be giving way to entrepreneurialism," commented Arnold S. Relman, professor of medicine and social medicine at Harvard Medical School (Wekesser 66). This statement may have a great deal of bearing on reality. The tangled knot of insurers, physicians, drug companies, and hospitals that we call our health system are not as unselfish and focused on the patients' needs as people would like to think. Pharmaceutical companies are particularly ruthless, many of them spending millions of dollars per year to convince doctors to prescribe their drugs and to convince consumers that their specific brand of drug is needed in
Eli Lilly’s decision to create a joint venture was not surprising (figure 1). The India government limited foreign direct investment to 51%, importing was subject to manufacturing at high costs outside the country and then paying high importation tariffs, and licensing was not prudent due to an absolute lack of product patents laws that were needed to protect Eli Lilly’s intellectual property.
This casebook concentrates on the negative effects that the pharmaceutical industry’s trade and production policies have on third world nations suffering from disease epidemics. My position is that pharmaceutical companies are not concerned with the health benefits of their drugs, but rather with the market that their drugs generate. I illustrate this notion by describing the trade policies that pharmaceutical companies influence and the pharmaceutical companies’ production policies which concentrate on producing life-style drugs rather than drugs that cure life-threatening diseases.
The dependency of profits to promote sales to please shareholders and research and development of new products seem to be the mindset of the pharmaceutical industry. It is without question that the pharmaceutical companies only care about making a profit more than they do to help the people of the United States. Pharmaceutical companies and doctors that represent them are only acting in their own best interest; patients are the ones who are suffering the most. With that, new information being produced it is not always being fully disclosed in the fine print, or the other option to the drugs they take, this just only helps fuel business’s.
In 1970 the government passed two new regulations that has effect on the pharmaceutical industry. “The India Patent Act prohibited
On September 2nd 2011, a Twenty-four year old man from Cincinnati named Kyle Willis´ fell victim to the corruption of the pharmaceutical industry(Gann, Carrie). Willis had a severe toothache on his wisdom tooth that resulted in its extraction. After the surgery, Willis´s face started to swell and was sent to the emergency room. He was prescribed antibiotic medications and also painkillers in order to follow standard recovery procedure. Kyle Willis’ could not afford both drugs so he just purchased the pain killers because of the swelling unbearable pain. The infection continued to spread into his brain which lead to severe brain swelling and eventually Kyle Willis’ death. Kyle Willis’ died because he could not afford the medication that
These are some of the reasons why the pharmaceutical companies think it is better to go out of the country so that they can make money there. In almost all the other countries of the world, the branded medicines are used
We analyzed the Indian Pharmaceutical industry on these five forces and the findings of industry competitiveness and profitability are written under the relevant competitive forces.
India makes an interesting case study in this regard, where the local drug manufacturers like Biocon and Ranbaxy have had joint ventures with the pharmaceutical companies in the US and EU respectively. There is a mutual benefit for companies in both developed and developing countries (Europe Economics, 2001) i.e. developed countries could manufacture the required drugs in a ‘cheaper’ environment while developing countries could benefit from the technology, knowledge and experience transfer from the other side.
Therefore, protection of patents is one of the key conditions necessary for further development of the pharmaceutical industry. At the same time, non-efficient legislation that does not provide the necessary level of patent protection is one of the factors that hamper expansion of “Big Pharmaceutical” companies to the developing countries8.
India must seriously examine its Intellectual Property Rights (IPR) position and see how best TRIPS (Trade Related Intellectual Property Rights) can be interpreted, as IPR laws are national laws. India should cull the best points from various laws to suit her future needs.
Another important feature of the pharmaceutical industry was the fact in that in many countries it was